TriangleDISEASE & TREATMENT SETTING
Acute Myeloid Leukemia
Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.
Exact scope
Acute Myeloid Leukemia
- Source population
- Not part of this definition
- Disease extent
- Not part of this definition
- Treatment line
- Not part of this definition
- Stage
- Not part of this definition
- Resectability
- Not part of this definition
Biomarkers, prior therapy and derivation
- molecular
- prior therapy
- derivation status
- source-attested
- derivation note
- Derived from NCI topic(s): Acute Myeloid Leukemia. Strongest NCIt resolution: exact. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
- source wording
- Source null
17 more-specific settings
Mylotarg: refractory acute myeloid leukemia →TIBSOVO: acute myeloid leukemia with IDH1 stated without a specific alteration →ONUREG: acute myeloid leukemia after prior therapy →VANFLYTA: acute myeloid leukemia with FLT3 stated without a specific alteration (maintenance) after prior therapy →Idhifa: refractory acute myeloid leukemia with IDH2 stated without a specific alteration →RYDAPT: acute myeloid leukemia with FLT3 mutation →TIBSOVO: acute myeloid leukemia with IDH1 stated without a specific alteration, IDH1 mutation →REZLIDHIA: refractory acute myeloid leukemia with IDH1 stated without a specific alteration →Komzifti: refractory acute myeloid leukemia →REZLIDHIA: refractory acute myeloid leukemia with IDH1 stated without a specific alteration, IDH1 mutation →Revuforj: refractory acute myeloid leukemia →Xospata: refractory acute myeloid leukemia with FLT3 mutation →Xospata: refractory acute myeloid leukemia with FLT3 stated without a specific alteration →TIBSOVO: refractory acute myeloid leukemia with IDH1 stated without a specific alteration →Acute Myeloid Leukemia →recurrent Acute Myeloid Leukemia →Acute Myeloid Leukemia →
Study evidence for this setting
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematolog
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating P
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
Indication-specific source history
2025-01-21 · treosulfan with fludarabine · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-myeloid-leukemia
- event id
- notice-2ca0cbc965c16733
- event date
- 2025-01-21
- event kind
- approval-notification
- drug or regimen
- treosulfan with fludarabine
- source indication text
- FDA approved treosulfan, an alkylating agent, with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in adult and pediatric patients 1 year of age and older with acute myeloid leukemia or myelodysplastic syndrome .
- match phrase
- acute myeloid leukemia
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-eed3ef224dcd705a
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-10-24 · revumenib · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-myeloid-leukemia
- event id
- notice-2eae4c9542038c17
- event date
- 2025-10-24
- event kind
- approval-notification
- drug or regimen
- revumenib
- source indication text
- FDA approved revumenib, a menin inhibitor, for relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation in adult and pediatric patients 1 year and older who have no satisfactory alternative treatment options.
- match phrase
- acute myeloid leukemia
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-61ed478e73d4f4a0
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2025-11-13 · ziftomenib · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-myeloid-leukemia
- event id
- notice-49f6e1bf9bf6cceb
- event date
- 2025-11-13
- event kind
- approval-notification
- drug or regimen
- ziftomenib
- source indication text
- FDA approved ziftomenib, a menin inhibitor, for adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options.
- match phrase
- acute myeloid leukemia
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-970653d3c34dd8d5
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
2026-05-13 · oral combination of decitabine and cedazuridine tablets with venetoclax · approval notification
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-myeloid-leukemia
- event id
- notice-9745708a2498f506
- event date
- 2026-05-13
- event kind
- approval-notification
- drug or regimen
- oral combination of decitabine and cedazuridine tablets with venetoclax
- source indication text
- FDA approved an oral combination of decitabine and cedazuridine tablets with venetoclax for the treatment of newly diagnosed acute myeloid leukemia in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.
- match phrase
- acute myeloid leukemia
- match status
- candidate
- status category
- Source null
- has date discrepancy
- 0
- source collection
- fda-approval-notice
- source key
- fda-990c1df07ad6d6a2
- curation status
- draft
- reviewed by
- Source null
- reviewed at
- Source null
- created at
- 2026-09-10T00:00:00Z
Source relationships and population-mapping limitations
- bindings
- release id
- clinical-indications-draft-1
- disease state id
- ds-acute-myeloid-leukemia
- binding id
- ncit-C3171
- source collection
- ncit-concept
- source key
- C3171
- source excerpt
- Source null
- match status
- exact
- match note
- Source null
- recorded at
- 2026-09-10T00:00:00Z
- mappings
Download this complete draft source relationship record →
Preserved source evidence · Not medical advice